News From #ASCO22 Part 3, Addressing Challenges in Ovarian Cancer

I watched this gyn cancer Education Session a day later. I appreciate that ASCO provides participants access to the videos after the session has run.

Homologous Recombination Proficient disease

Watched on demand
6/5
Challenges in OC #ASCO22 #gyncsm @SwisherLiz
Maintenance options with HR proficient Disease
(HRP mechanism by which DNA damage can be corrected)
HRP is not a driver event.
Some benefit and high cost of PARP use in those without HR deficiency, pic.twitter.com/8wszbexlzh

— Dee Sparacio (@womenofteal) June 6, 2022

Repeating PARP maintenance in ovarian cancer recurrence may have only a small benefit.

Watched on demand
6/5 #ASCO22 #gyncsm
Challenges in OC @CoquardRay
Recurrent Maintenance Options in Patients With Prior Maintenance Therapy
PARP use in maintenance has improved PFS.
Repeat PARP benefit is small
Evidence supports use of Bev pic.twitter.com/bjzSCIOzsl

— Dee Sparacio (@womenofteal) June 6, 2022

 

 

Watched on demand
6/5 #ASCO22 #gyncsm
Challenges in OC @CoquardRay presents good ?'s for patients and survivors:
Should Endpoints be weighted for PRO and QOL?
What are patient expectations? pic.twitter.com/OTAm2VDpCx

— Dee Sparacio (@womenofteal) June 6, 2022

HIPEC  

 
 6/5
Challenges in OC #ASCO22 #gyncsm
Van Driel - HIPEC: Is It Ready for Prime Time in Ovarian Cancer?
Multidisciplinary team and surgical skills needed to use HIPEC.

Use Hipec in combo with Cytoreductive surgery. pic.twitter.com/CbBoHthWvP

— Dee Sparacio (@womenofteal) June 6, 2022

 

Check back on Monday for my take on the Gyn Cancer Poster Discussion session.

Dee

Every Day is a Blessing!